TE
科技回声
首页24小时热榜最新最佳问答展示工作
GitHubTwitter
首页

科技回声

基于 Next.js 构建的科技新闻平台,提供全球科技新闻和讨论内容。

GitHubTwitter

首页

首页最新最佳问答展示工作

资源链接

HackerNews API原版 HackerNewsNext.js

© 2025 科技回声. 版权所有。

Global Cystic Fibrosis Therapeutics Market to Reach $46.8B by 2030

7 点作者 trifit大约 2 年前

1 comment

bdcravens大约 2 年前
I have CF, and it&#x27;s great to see this market growing. The latest &quot;wonder drug&quot;, Trikafta, has been a game changer.<p>* It eliminated most of my respiratory exacerbations - I used to have a hospital stay pretty much every spring, and haven&#x27;t had any since starting it. (VERY timely, considering I started it just before the pandemic, and who knows what would have happened had I been admitted during that time)<p>* I also used to be underweight, and I now worry about losing weight (though gaining the weight during the pandemic was inconvenient, as for several months buying new clothes was tricky)<p>CF slowly irreparably damages various organs like the lungs and pancreas, and being 45, I&#x27;ll never be &quot;cured&quot; as those systems have been effected. However, it&#x27;s exciting to know that someone born with CF today may not ever experience that, but rather, just live a long normal life where they just take a few pills each day. (When I was born, I think the life expectancy was 7)<p>Obviously cost is an issue - it&#x27;s VERY expensive. (retail $20k+ per MONTH) I have the best insurance my employer offers, and a great income, but many don&#x27;t, and their copay assistance now caps out at $20k&#x2F;year, so this can be a challenge. Many countries have better healthcare of course, but each new iteration of modulator (the category Trikafta falls into) tends to have a much longer approval cycle than in the US, with cost being a prime factor.
评论 #35216510 未加载